

## **REMARKS**

Reconsideration of the subject application is requested in view of the above amendments and the following Remarks.

**I. Claim Status/Amendments.** Claims 9 and 10 have been cancelled without prejudice or disclaimer. Claims 1-8, 11, 12 and 13-19 have been amended, without prejudice or disclaimer. By this Amendment, claims 1-8 and 11-20 are pending. Support for the amended claims is found throughout the specification, e.g., at page 3, lines 7-23; page 6, lines 17-18; page 7, lines 1-10; page 10, lines 26-30; page 11, lines, 16-30; page 13, lines 9-22; and original claims 1-20. Applicants note particularly that the specification supports the term “prothrombin-converting enzyme” that is recited in amended claims 1, 4 and 13. The specification refers, e.g., to “prothrombinase” as “any substance which converts prothrombin to thrombin” (specification at page 6, lines 17-18). The specification further refers the terms “prothrombinase substrate” and prothrombinase product” as “the substrate and product involved in prothrombinase-mediated catalysis” (specification at page 7, lines 1-3). Example 1 further describes measuring the product produced by, among other reactions, a reaction of normal or actylated prothrombin, factor Xa, plus either PS:PC or platelets, and calcium chloride (specification at page 16, lines 13-15). These passages convey to one of ordinary skill in the art that when the application was filed Applicants had possession of a mixture comprising a “prothrombin-converting enzyme,” as set forth in the claims. Ipsis verbis recitation of the term used in the claim is not required.

Each amendment to the claims is supported by the application as filed.

Accordingly, by this Amendment, no new matter has been added to the application.

**II. Claim Rejections.** The claim rejections set forth in the Office Action are summarized and addressed as follows:

(i) Rejections Under 35 U.S.C. § 112, first paragraph (enablement). Claims 1-3 have been rejected as being directed to a method comprising “detecting the catalysis” of a prothrombinase. In response, without conceding the validity of the rejections, claims 1-3 have been amended. The amended claims are directed to “a method for assaying activation state of platelets,” comprising steps (a) and (b), as set forth in claim 1. The amendments to claims 1-3 are believed to address and overcome the basis of the rejections. Reconsideration of claims 1-3 and withdrawal of all rejections thereof under 35 U.S.C. § 112, first paragraph for lack of enablement is requested, accordingly.

(ii) (i) Rejections Under 35 U.S.C. § 112, second paragraph. Claims 1-12 have been rejected as allegedly indefinite for including the term “detecting.” The Examiner’s position is that it is not known what catalytic entity is to undergo or receive “detecting.” In response, without conceding the validity of the rejections or the Examiner’s position, the claims 1-8, 11 and 12 have been amended. Claims 9 and 10 have been cancelled.

Claims 1-8, 11, and 12 are now directed to a method for assaying platelet activation state. The method comprises providing a mixture comprising platelets, a prothrombin-converting enzyme, and a substrate for the prothrombin-converting enzyme, and assaying the production of a product produced in the mixture, which product does not activate platelets (see amended claim 1). Each of claims 2-8, 11, and 12 depend either directly or indirectly from claim 1 and are therefore, likewise, directed to a method comprising providing a mixture comprising platelets, a prothrombin-converting enzyme, and a substrate for the prothrombin-converting enzyme, and assaying the production of a product produced in the mixture, which product does not activate platelets. The basis of the present rejection of remaining claims 1-8, 11, and 12 is therefore believed to have been addressed and overcome.

The Examiner has objected to the term “associated” in claim 1. In response, without conceding the validity of the Examiner’s position, claim 1 has been amended. The phrase “a prothrombinase which is associated with the platelet” does not appear in the amended claim. The basis of the present rejection is believed to have been addressed and overcome.

The Examiner has objected to recitation of the phrase “modified prothrombinase substrate” that appeared in claims 1-3, 5-7, 13, 15, and 16. In response, without conceding the validity of the Examiner’s position, the claims have been amended and are now directed, in relevant part, simply to a “substrate.” The basis of the present rejections is believed to have been addressed and overcome.

For all of the reasons set forth above, all rejections of pending claims 1-8, 11-13, 15, and 16 under 35 U.S.C. § 112, second paragraph are believed to have been addressed and overcome. Reconsideration of pending claims 1-8, 11-13, 15, and 16 and withdrawal of all rejections thereof for alleged indefiniteness is requested, accordingly.

(iii) Rejections Under 35 U.S.C. § 102. Claims 1-5, 9-11, 13, 15, 17, 19, and 20 have been rejected as allegedly anticipated by Szczeklik et al., *Blood* 80:2006-2011 (1992) (“Szczeklik et al.”). The rejections are traversed on the grounds that Szczeklik et al. fail to disclose the claimed invention.

Szczeklik et al. does not anticipate the claimed method because fails Szczeklik fails to teach a method comprising converting a modified prothrombinase-converting enzyme substrate (e.g., modified prothrombin) to a product which does not activate platelets (e.g., modified thrombin) and assaying the presence of the product. The Examiner’s basis for asserting lack of novelty is based in part on the assertion that Szczeklik et al. describe a method for assaying the activation state of a platelet by measuring thrombin generation. Office Action at



evidence that Szczeklik et al. react a modified prothrombin with prothrombinase. Nor, in any event, do Szczeklik et al. describe assaying for any prothrombinase product other than thrombin.

In view of the foregoing, Szczeklik et al. does not anticipate the claimed invention. Where a reference fails to teach an element of an invention, it cannot anticipate that invention. Reconsideration of pending claims 1-5, 10, 11, 13, 15, 17, and 19-20 and withdrawal of the rejection thereof under 102(b) is requested, accordingly.

*(iv) Rejections Under 35 U.S.C. § 103.* Claims 8 and 14 are rejected as allegedly obvious over Szczeklik et al. in view of Phizicky & Fields, 59 Microbiol. Rev. 94 (1995) (“Phizicky & Fields”). Claims 12, 14, and 18 are rejected as allegedly obvious over Szczeklik et al. in view of Mattler & Bang, Thromb. Haemost. 38:776 (1977) (“Mattler & Bang”). The rejections are respectfully traversed, as follows.

In making the obviousness rejections, the Examiner relies on Szczeklik et al. as the primary reference. Each of the rejected claims is directed to production and assay of a modified prothrombinase product which does not activate platelets. (See: Claim 1, base claim for claims 8 and 12; claim 13, base claim for claims 14 and 18.) As discussed above, Szczeklik et al. fails to disclose a method comprising converting a prothrombinase substrate to a modified prothrombinase product which does not activate platelets and assaying the presence of the modified product. Moreover, Szczeklik et al. lacks any suggestion whatsoever to modify a prothrombinase substrate to yield a modified prothrombinase product that does not activate platelets and assay formation of the modified product. The claims are therefore not obvious over Szczeklik et al. The Examiner cites Phizicky & Fields merely for the proposition that it would have been obvious to use plasmon resonance to measure protein concentration. Office Action at page 6. Without conceding the Examiner’s position, however, Phizicky & Fields cannot cure the

defect in Szczeklik et al. because Phizicky & Fields fail to suggest production and assay of a modified prothrombinase product which does not activate platelets. Similarly, the Examiner cites Mattler & Bang merely for the proposition that it would have been obvious to use a chromogenic substrate in order to detect thrombin activity. Without conceding the Examiner's position, however, Mattler & Bang cannot cure the defect in Szczeklik et al. because Mattler & Bang fail to suggest production and assay of a modified prothrombinase product which does not activate platelets. Accordingly, neither Szczeklik et al. alone, nor Szczeklik et al. in combination with either Phizicky & Fields or Mattler & Bang suggests production and assay of a modified prothrombinase product which does not activate platelets. Accordingly, the obvious rejections should be withdrawn.

For the reasons set forth above, the claims are not obvious over Szczeklik et al. in view of Phizicky & Fields nor over Szczeklik et al. in view of Mattler & Bang. Reconsideration of claims 8, 12, 14, and 18 and withdrawal of the rejections thereof under rule 103(a) is requested accordingly.

### CONCLUSION

In view of the above amendments and remarks, it is respectfully requested that the application be reconsidered and that all pending claims be allowed and the case passed to issue.

If there are any other issues remaining, which the Examiner believes could be resolved through either a Supplemental Response or an Examiner's Amendment, the Examiner is respectfully requested to contact the undersigned at the telephone number indicated below.

Respectfully submitted,

By 

Mitchell Bernstein, Ph.D.

Registration No.: 46,550

Agent for Applicant(s)

Dated: October 25, 2004

Application No.: 10/031,092  
Amendment Under 37 C.F.R. § 1.111

Docket No.: 00974/100F828-US1

Page 11

{W:\00974\100F828000\00245317.DOC [REDACTED]}

Application No.: 10/031,092  
Amendment Under 37 C.F.R. § 1.111

{W:\00974\100F828000\00245317.DOC { 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034